{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:42:16Z","timestamp":1785526936615,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00 CA252005"],"award-info":[{"award-number":["R00 CA252005"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["Junior Faculty Scholar"],"award-info":[{"award-number":["Junior Faculty Scholar"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Institutional Research Grant (University of Cincinnati)"],"award-info":[{"award-number":["Institutional Research Grant (University of Cincinnati)"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Cincinnati Cancer Center Pilot Award"},{"name":"Carey & Stella Wamsley Charitable Trust"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in the RAS\/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving\n                    <jats:italic>NRAS<\/jats:italic>\n                    and\n                    <jats:italic>KRAS<\/jats:italic>\n                    . In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in AML and are associated with poor outcomes. To date, no comprehensive analysis has assessed the clinical and molecular characteristics of\n                    <jats:italic>BRAF-<\/jats:italic>\n                    mutated AML. In this study, we report the identification of canonical and non-canonical\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutations in ~1% of 5779 consecutive clinically and molecularly fully annotated AML patients treated at two major United States Cancer Centers (50\/5779 AML patients: 21 newly diagnosed AML; 9 relapsed\/refractory; 20 newly diagnosed secondary AML). We performed single-cell multiomic analysis on a subset of AML samples.\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutations were enriched in myelodysplasia-related AML (AML-MR), and most mutations were located outside the V600 hotspot. Single-cell multiomic profiling delineated\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutation class-specific patterns of co-mutations, clonality, and immunophenotypes. Notably,\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutations and other signaling co-mutation(s) could be found in the same cell, a finding that significantly diverges from prior studies of\n                    <jats:italic>RAS<\/jats:italic>\n                    -mutant AML. In this cohort,\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant AML patients had poor overall survival with currently available treatments, including venetoclax-based regimens. Drug sensitivity data suggest possible avenues for targeted treatment of\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutated AML.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02996-1","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:56:18Z","timestamp":1781506578000},"page":"1688-1697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Darren","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Abu-Shihab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Plas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deedra","family":"Nicolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-5063","authenticated-orcid":false,"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Laganson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-730X","authenticated-orcid":false,"given":"Andrew J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1348","authenticated-orcid":false,"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-5908","authenticated-orcid":false,"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-8748","authenticated-orcid":false,"given":"Robert L.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-0960","authenticated-orcid":false,"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-1419","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-2842","authenticated-orcid":false,"given":"Linde A.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2996_CR1","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124:3947\u201355.","journal-title":"Blood"},{"key":"2996_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2996_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2996_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1535-7163.MCT-15-0643","volume":"15","author":"ML Turski","year":"2016","unstructured":"Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, et al. Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol Cancer Ther. 2016;15:533\u201347.","journal-title":"Mol Cancer Ther"},{"key":"2996_CR5","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183\u201399.","journal-title":"Oncogene"},{"key":"2996_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251\u201363.","journal-title":"Cell"},{"key":"2996_CR7","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305\u201315.","journal-title":"N Engl J Med"},{"key":"2996_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"2996_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2018.01.021","volume":"33","author":"PK Ng","year":"2018","unstructured":"Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, et al. Systematic functional annotation of somatic mutations in cancer. Cancer Cell. 2018;33:450\u201362.e10.","journal-title":"Cancer Cell"},{"key":"2996_CR10","doi-asserted-by":"publisher","first-page":"eadp2742","DOI":"10.1126\/science.adp2742","volume":"388","author":"H Lavoie","year":"2025","unstructured":"Lavoie H, Jin T, Lajoie D, Decossas M, Gendron P, Wang B, et al. BRAF oncogenic mutants evade autoinhibition through a common mechanism. Science. 2025;388:eadp2742.","journal-title":"Science"},{"key":"2996_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209\u201321.","journal-title":"Cell"},{"key":"2996_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234\u20138.","journal-title":"Nature"},{"key":"2996_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2996_CR14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2996_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e9.","journal-title":"Cancer Cell"},{"key":"2996_CR16","first-page":"2679","volume":"130","author":"CY Ok","year":"2017","unstructured":"Ok CY, Singh R, Luthra R, Hatfield D, Floyd K, Loghavi S, et al. Endleukemia assay v1: enabling NGS-based comprehensive routine molecular profiling of leukemias in routine clinical care. Blood. 2017;130:2679.","journal-title":"Blood"},{"key":"2996_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482\u201395.","journal-title":"Blood Adv"},{"key":"2996_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/leu.2017.86","volume":"31","author":"AK Eisfeld","year":"2017","unstructured":"Eisfeld AK, Mrozek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211\u20138.","journal-title":"Leukemia"},{"key":"2996_CR19","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1038\/s41588-024-01929-x","volume":"56","author":"A Stiff","year":"2024","unstructured":"Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, et al. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024;56:2434\u201346.","journal-title":"Nat Genet"},{"key":"2996_CR20","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1158\/1078-0432.CCR-23-1674","volume":"30","author":"G Qin","year":"2024","unstructured":"Qin G, Dai J, Chien S, Martins TJ, Loera B, Nguyen QH, et al. Mutation patterns predict drug sensitivity in acute myeloid leukemia. Clin Cancer Res. 2024;30:2659\u201371.","journal-title":"Clin Cancer Res"},{"key":"2996_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587:477\u201382.","journal-title":"Nature"},{"key":"2996_CR22","doi-asserted-by":"publisher","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","volume":"9","author":"TM Robinson","year":"2023","unstructured":"Robinson TM, Bowman RL, Persaud S, Liu Y, Neigenfind R, Gao Q, et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9:eadg0488.","journal-title":"Sci Adv"},{"key":"2996_CR23","doi-asserted-by":"publisher","unstructured":"Drucker M, Lee D, Zhang X, Kain B, Bowman M, Nicolet D, et al. Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis. Blood https:\/\/doi.org\/10.1182\/blood.2025030772 (2026).","DOI":"10.1182\/blood.2025030772"},{"key":"2996_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289\u201396.","journal-title":"Nat Methods"},{"key":"2996_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/ncb1757","volume":"10","author":"H Nojima","year":"2008","unstructured":"Nojima H, Adachi M, Matsui T, Okawa K, Tsukita S, Tsukita S. IQGAP3 regulates cell proliferation through the Ras\/ERK signalling cascade. Nat Cell Biol. 2008;10:971\u20138.","journal-title":"Nat Cell Biol"},{"key":"2996_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11:5327.","journal-title":"Nat Commun"},{"key":"2996_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241\u201350.","journal-title":"Nature"},{"key":"2996_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"2996_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2996_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"2996_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"2996_CR32","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144:2211\u201322.","journal-title":"Blood"},{"key":"2996_CR33","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","volume":"11","author":"JE Karp","year":"2005","unstructured":"Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005;11:8403\u201312.","journal-title":"Clin Cancer Res"},{"key":"2996_CR34","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.xcrm.2025.102526","volume":"7","author":"ML Stewart","year":"2026","unstructured":"Stewart ML, Gibbs J, Watanabe-Smith K, Nguyen A, Kenna I, Thiel-Klare K, et al. CDK4\/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. Cell Rep Med. 2026;7:102526.","journal-title":"Cell Rep Med"},{"key":"2996_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596\u20139.","journal-title":"Nature"},{"key":"2996_CR36","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694\u2013703.","journal-title":"N Engl J Med"},{"key":"2996_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128\u201335.","journal-title":"Nat Med"},{"key":"2996_CR38","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","volume":"13","author":"DB Solit","year":"2007","unstructured":"Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007;13:1775\u201382.","journal-title":"Clin Cancer Res"},{"key":"2996_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25:388\u201399.","journal-title":"Lancet Oncol"},{"key":"2996_CR40","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1080\/10428194.2024.2347539","volume":"65","author":"T Abuasab","year":"2024","unstructured":"Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, et al. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma. 2024;65:1344\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2996_CR41","doi-asserted-by":"crossref","unstructured":"George GV, Evans AG, Jajosky AN. BRAF V600E-mutant acute myeloid leukemia: a case series and literature review of a rare entity. Genes. 2024;15:1383.","DOI":"10.3390\/genes15111383"},{"key":"2996_CR42","doi-asserted-by":"crossref","unstructured":"Fei F, Caporale C, Chang L, Fortini BK, Ali H, Bell D, et al. BRAF mutations in patients with myeloid neoplasms: a cancer center multigene next-generation sequencing analysis experience. Int J Mol Sci. 2024;25:5183.","DOI":"10.3390\/ijms25105183"},{"key":"2996_CR43","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-17-3384","volume":"24","author":"M Dankner","year":"2018","unstructured":"Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, et al. Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas. Clin Cancer Res. 2018;24:6483\u201394.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02996-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:06:33Z","timestamp":1785521193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02996-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2996"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02996-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LAM and RLB had previously received honoraria for speaking arrangements and had previously served on a Speakers Bureau for Mission Bio, Inc. JCB has ownership interest in Vincera, an advisory and consultancy role with Novartis, Syndax, and Vincera, research funding from Genentech, Janssen, Acerta, and Pharmacyclics, an AbbVie company. A-KE has received an honorarium from AstraZeneca for serving on their Diversity, Equity, and Inclusion Advisory Board and has received a research grant from Novartis. Spouse of A-KE has ownership interest in Karyopharm Therapeutics. SL has research funding from Amgen and Astellas and has received honoraria\/consultation fees from Abbvie, Arima, BMS, Caris, Cogent, Daiichi Sankyo, Johnson and Johnson, Kura Oncology, Qiagen, Recordati, Servier, Stemline Therapeutics, Syndax, Tempus AI. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Authors confirm that all methods described in the study were performed in accordance with relevant institutional guidelines and regulations. This study was approved by CCHMC IRB (protocol 2022-0806, multiomic profiling of de-identified samples), OSU IRB (protocol 2023C0062), MDACC IRB (protocol PA17-0485), and OHSU IRB (protocols 9570; 4422, for ex vivo drug assays\/multiomic profiling). The authors confirm that patient consent was obtained all study participants according to institutional IRB approved protocols in accordance with the Declaration of Helsinki. Patients treated on Alliance for Clinical Trials in Oncology (Alliance) protocols gave informed consent for tissue banking and sequencing under CALGB 9665 and 20202. No clinical and\/or outcome data analyses were performed on these patients. No live vertebrate studies were performed. This study did not include any identifiable images.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}